Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD) - who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT) - for whom intravitreal injection has already been clinically indicated Who Should NOT Join This Trial: - Patients younger than 45 years or older than 90 years - History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months - Presence of uveitis - Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract) - Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema) - Presence of hereditary retinal dystrophies - Presence of optic atrophy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD) * who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT) * for whom intravitreal injection has already been clinically indicated Exclusion Criteria: * Patients younger than 45 years or older than 90 years * History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months * Presence of uveitis * Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract) * Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema) * Presence of hereditary retinal dystrophies * Presence of optic atrophy

Treatments Being Tested

DRUG

Aflibercept biosimilar (MY-1701P)

Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.

Locations (1)

Prof. Dr. Cemil Taşcıoğlu City Hospital
Istanbul, şişli, Turkey (Türkiye)